Legislation & Advocacy

Americans for Ibogaine is committed to advancing policies that support FDA-approved ibogaine research in the United States. We work to educate lawmakers, researchers, and key stakeholders on ibogaine’s potential as a breakthrough medical treatment for substance use disorder and mental health conditions. By advocating for science-backed regulatory pathways, we aim to position the U.S. as a leader in ibogaine research and expand access to innovative treatment options for those in need.

This state-by-state tracker summarizes proposed and enacted bills, funding measures, and research initiatives aimed at evaluating ibogaine’s potential role in addiction and mental health treatment.

The legislative updates below were last revised in October 2025.

ARIZONA

• October 2025: Arizona researchers can now apply for $5 million to study Ibogaine! The state has released a $5 million RFP to fund phase I clinical trials, signaling a major investment in early-stage medical research.

• June 2025: House Bill 2871, sponsored by Arizona state representative Justin Wilmeth (R), which seeks funding for ibogaine research, was signed into law on June 27 as part of the state budget. Arizona joins Texas in funding FDA-approved clinical trials.

• March 2025: The Arizona House of Representatives approved funding for ibogaine research for veterans with PTSD and TBI.

  “Every single day, we lose veterans to PTSD and traumatic brain injuries, and the treatment options available now just aren’t good enough,” said the bill’s sponsor, Representative Justin Wilmeth (R). “I urge my colleagues in the Senate to join the House in passing HB2871. Let’s make Arizona the leader in real solutions for our veterans.”

• February 2025: Arizona state representative Justin Wilmeth (R) introduced House Bill 2871, which would designate $10 million from the state’s general fund to study ibogaine in the treatment of neurological diseases, including traumatic brain injury and PTSD.

  In a press release, Wilmeth pointed to other Republican politicians, including Congressman Morgan Luttrell and former Texas governor Rick Perry, as ibogaine advocates.

CALIFORNIA

• October 2025: Governor Gavin Newsom (D) just signed AB 1103, a veteran-backed bill to accelerate the study of psychedelics for PTSD and mental health. This bill streamlines California’s approval process for federally authorized clinical research involving Schedule I and II substances such as psilocybin, MDMA, and ibogaine, by allowing expedited review through a subcommittee of the state’s Research Advisory Panel.

COLORADO

• July 2025: As of now, ibogaine is not yet available for therapeutic use in Colorado. The state is developing the necessary regulations and infrastructure to incorporate ibogaine into its natural medicine program, with the potential for its future inclusion in the program. That said, Colorado lawmakers joined a growing number of voices calling for a closer look at ibogaine’s medical potential. You can read the full article here.

• June 2025: Colorado regulators are reportedly considering including iboga for therapeutic use within the state’s regulated psychedelics program. If approved, Colorado would become the first state to offer legal iboga services.

• July 2023: Colorado General Assembly enacted Senate Bill 23-290 to establish a regulatory framework for these substances. This legislation allows for the inclusion of ibogaine in the state's natural medicine program, contingent upon recommendations from the Natural Medicine Advisory Board and approval by the Director and the Executive Director of the State Licensing Authority. leg.colorado.gov

• November 2022: Colorado voters approved Proposition 122, known as the Natural Medicine Health Act, which decriminalized the possession, cultivation, and sharing of certain natural medicines, including ibogaine, for adults aged 21 and over.

KENTUCKY

• August 2025: Kentucky’s Interim Joint Committee on Health Services discussed joining a multi-state effort to study ibogaine as a treatment for neurological conditions, including opioid addiction. The idea originated in 2023, when the Kentucky Opioid Abatement Advisory Commission proposed using opioid settlement funds for ibogaine research. That plan was dropped after a new attorney general took office. Governor Andy Beshear has since expressed skepticism about ibogaine’s safety, and lawmakers have not scheduled further action, such as introducing a bill to fund research.

• February 2025: Kentucky State Senators Donald Douglas (R), Shelley Funke Frommeyer (R), and Lindsey Tichenor (R) introduced Senate Bill 240. SB240 would establish the intent of the General Assembly to determine if ibogaine is worthy of clinical research, trials, and studies as a potential viable therapeutic treatment of opioid dependence and any other co-occurring mental health disorders.

LOUISIANA

• JUNE 2025: Senate Resolution 186, introduced by Louisiana State Sen. Patrick McMath (R), would establish a task force to study the therapeutic use of psychedelics for veterans.

MASSACHUSETTS

• September 2025: Senate Bill 1400, sponsored by Sen. Cindy Friedman (D), received a favorable report from the Joint Committee on Mental Health, Substance Use, and Recovery and was referred to the Committee on Healthcare Financing.

• August 2025: S1400, introduced by Sen. Cindy Friedman (D), would direct the Department of Public Health to establish a pilot program for psychedelic-assisted treatments, which could include ibogaine.

MISSISSIPPI

• August 2025: Americans for Ibogaine CEO, W. Bryan Hubbard, testified before the state legislature’s Joint Committee on Public Health, outlining the potential of ibogaine to treat a range of neurological conditions. He discussed emerging evidence supporting ibogaine’s use for opioid use disorder, traumatic brain injury, and neurodegenerative diseases, as well as ongoing efforts in other states, including Texas, to fund FDA-supervised clinical trials. He was joined by AFI Ambassadors, TK and Cipriana Quann.

• May 2025: Efforts are underway in Mississippi to explore a new avenue of hope in the fight against PTSD and addiction. Lawmakers are preparing to file legislation that would support clinical trials for ibogaine, a plant-based compound showing promising results in addressing trauma and substance use challenges.

NEVADA

• March 2025: Nevada’s Assembly Bill 378 adopts recommendations from an interim study group formed under 2023 legislation to establish a facilitated access system for several psychedelics, including psilocybin, DMT, mescaline, and iboga. Access would initially be limited to military veterans and first responders diagnosed with a mental health condition. The bill has 24 sponsors—representing more than one-third of the legislature—including Assemblymembers Max Carter (D), Reuben D’Silva (D), Alexis Hansen (R), and Tracy Brown-May (D), as well as Senators Ira Hansen (R), Rochelle Nguyen (D), and Jeff Stone (R).

  Additionally, Senate Joint Resolution 10 was introduced to urge Congress to reform federal laws governing psychedelics, including efforts to reschedule them.

NEW YORK

• January 2025: New York State Senators Nathalia Fernandez (D) and Jacob Ashby (R) have introduced Senate Bill S1817, which would direct the Office of Addiction Services and Supports (OASAS) to facilitate clinical research on ibogaine as a potential treatment for heroin, methamphetamine, and cocaine addiction. The measure follows an earlier effort in the state to study ibogaine’s use in treating PTSD among veterans and first responders.

OREGON

• April 2025: House Bill 3817, sponsored by Rep. Alek Skarlatos (R) and Sen. David Brock Smith (R), would establish a medical market for ibogaine treatment. The bill leaves details about program administration and timelines to the state departments of health and veterans’ affairs and does not specify how Oregon would acquire ibogaine. Because the iboga plant does not grow natively in Oregon, the state may need a federal import license or develop a synthetic alternative. On April 16, the bill was referred to the Ways and Means Committee, with no indication yet of further action before adjournment in June.

TEXAS

• June 2025: On June 11th, Governor Greg Abbott (R) signed Senate Bill 2308 into law. SB2308 allocates funding for clinical trials exploring the pharmaceutical applications of ibogaine. The measure authorizes $50 million in grants for organizations capable of conducting FDA-supervised studies.

• March 2025: Texas continues to demonstrate leadership in medical innovation with House Bill 3717, introduced by Rep. Cody Harris (R), which would fund FDA-approved clinical trials of ibogaine—a potential breakthrough treatment for opioid use disorder, co-occurring substance use disorders, and other mental health conditions.

WASHINGTON

• January 2025: Washington State has introduced Senate Bill 5201, which would fund a three-year study on ibogaine’s effectiveness in treating opioid use disorder. The bill has bipartisan support from legislators including Sens. Jesse Salomon (D), T’wina Nobles (D), Jessica Bateman (D), Yasmin Trudeau (D), Liz Lovelett (D), Noel Frame (D), Mike Chapman (D), Robert Hasegawa (D), Lisa Wellman (D), Rebecca Saldaña (D), Jeff Holy (R), Curtis King (R), Mark Schoesler (R), and Jeff Wilson (R).